We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vaccines Get to America, but Congressional Relief Lacking
Read MoreHide Full Article
Market indexes began the day solidly in the green, but a bit of bearish trepidation crept in during the day, helping the Dow and S&P 500 finish down. The Dow, which had an intra-day high of +279 points, wound up closing down 186 points — lower by 0.62% on the day. The S&P 500 saw its fourth straight close in the red, following a strong showing earlier this month and last.
The Nasdaq closed up 0.5% on the day; it had been eyeballing a new all-time closing high, but fell short of that mark. It was led by Tesla (TSLA - Free Report) , +4.5% — one week from its official inclusion in the S&P 500, which will shore up Tesla investment across a wide swath of ETFs and mutual funds — and Alexion , +35% on reports that it will be bought out at a sizable premium by AstraZeneca (AZN - Free Report) . The small-cap Russell 2000 was up 0.11% on the day.
It’s a momentous day in the U.S., as the first Covid-19 front-line workers ceremoniously receive their first doses of the Pfizer (PFE - Free Report) -BioNTech (BNTX - Free Report) vaccine, but much of the success of the vaccine — indeed, of an outlook toward a pandemic-free global economy — has already been priced into valuations to an extent. The vaccine has rightly received the lion’s share of news headlines today, but it has not dictated the wary tone of market participants — an agreement (or lack thereof) for relief passed through Congress has.
Currently being discussed is the passage of $160 billion in State and Local aid with guardrails for distribution and certain liability protections for employers. What this does not include is any sort of direct stimulus — say, the $1200 one-time checks sent to each household endorsed by Bernie Sanders (I - Vermont), among others — and has a far smaller price tag than what the House had already passed twice, named the Heroes Act. Common sense may lead us to believe some relief is better than none, but common sense doesn’t always have a place at the congressional table.
So if there is a relief bill passed, it will likely be much less robust than many investors had been considering. It would also make very likely the need for further stimulus in 2021, prior to the considered date where every American who wants a Covid-19 vaccine will have one. Only then will we have a true semblance of our old economy back, and not before.
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Image: Bigstock
Vaccines Get to America, but Congressional Relief Lacking
Market indexes began the day solidly in the green, but a bit of bearish trepidation crept in during the day, helping the Dow and S&P 500 finish down. The Dow, which had an intra-day high of +279 points, wound up closing down 186 points — lower by 0.62% on the day. The S&P 500 saw its fourth straight close in the red, following a strong showing earlier this month and last.
The Nasdaq closed up 0.5% on the day; it had been eyeballing a new all-time closing high, but fell short of that mark. It was led by Tesla (TSLA - Free Report) , +4.5% — one week from its official inclusion in the S&P 500, which will shore up Tesla investment across a wide swath of ETFs and mutual funds — and Alexion , +35% on reports that it will be bought out at a sizable premium by AstraZeneca (AZN - Free Report) . The small-cap Russell 2000 was up 0.11% on the day.
It’s a momentous day in the U.S., as the first Covid-19 front-line workers ceremoniously receive their first doses of the Pfizer (PFE - Free Report) -BioNTech (BNTX - Free Report) vaccine, but much of the success of the vaccine — indeed, of an outlook toward a pandemic-free global economy — has already been priced into valuations to an extent. The vaccine has rightly received the lion’s share of news headlines today, but it has not dictated the wary tone of market participants — an agreement (or lack thereof) for relief passed through Congress has.
Currently being discussed is the passage of $160 billion in State and Local aid with guardrails for distribution and certain liability protections for employers. What this does not include is any sort of direct stimulus — say, the $1200 one-time checks sent to each household endorsed by Bernie Sanders (I - Vermont), among others — and has a far smaller price tag than what the House had already passed twice, named the Heroes Act. Common sense may lead us to believe some relief is better than none, but common sense doesn’t always have a place at the congressional table.
So if there is a relief bill passed, it will likely be much less robust than many investors had been considering. It would also make very likely the need for further stimulus in 2021, prior to the considered date where every American who wants a Covid-19 vaccine will have one. Only then will we have a true semblance of our old economy back, and not before.
Questions or comments about this article and/or its author? Click here>>
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Click to get it free >>